EPHX2 and Autoimmunity: In preclinical rodent studies, the sEH inhibitor (sEHI) 1-(4-trifluoro-methoxyphenyl)-3-(1-propionylpiperidin-4-yl) urea (TPPU) has been reported to ameliorate ongoing inflammation and fibrosis in multiple organs including the lung and kidney (Guan et al. 2021; Shi et al. 2022) and various autoimmune conditions (Trindade-da-Silva et al. 2017; Klocke et al. 2019; Jonnalagadda et al. 2021).